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Aims Heart failure (HF) is a pro-thrombotic state. Both platelet and vascular responses to nitric oxide (NO) donors are
impaired in HF patients with reduced ejection fraction (HFrEF) compared with healthy volunteers (HVs) due to
scavenging of NO, and possibly also reduced activity of the principal NO sensor, soluble guanylate cyclase (sGC),
limiting the therapeutic potential of NO donors as anti-aggregatory agents. Previous studies have shown that nitrite
inhibits platelet activation presumptively after its reduction to NO, but the mechanism(s) involved remain poorly
characterized. Our aim was to compare the effects of nitrite on platelet function in HV vs. HF patients with pre-
served ejection fraction (HFpEF) and chronic atrial fibrillation (HFpEF–AF), vs. patients with chronic AF without HF,
and to assess whether these effects occur independent of the interaction with other formed elements of blood.
....................................................................................................................................................................................................
Methods
and results
Platelet responses to nitrite and the NO donor sodium nitroprusside (SNP) were compared in age-matched HV
controls (n = 12), HFpEF–AF patients (n = 29), and chronic AF patients (n = 8). Anti-aggregatory effects of nitrite
in the presence of NO scavengers/sGC inhibitor were determined and vasodilator-stimulated phosphoprotein
(VASP) phosphorylation was assessed using western blotting. In HV and chronic AF, both nitrite and SNP inhibited
platelet aggregation in a concentration-dependent manner. Inhibition of platelet aggregation by the NO donor SNP
was impaired in HFpEF-AF patients compared with healthy and chronic AF individuals, but there was no impairment
of the anti-aggregatory effects of nitrite. Nitrite circumvented platelet NO resistance independently of other blood
cells by directly activating sGC and phosphorylating VASP.
....................................................................................................................................................................................................
Conclusion We here show for the first time that HFpEF-AF (but not chronic AF without HF) is associated with marked impair-
ment of platelet NO responses due to sGC dysfunction and nitrite circumvents the ‘platelet NO resistance’ phe-
nomenon in human HFpEF, at least partly, by acting as a direct sGC activator independent of NO.
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1. Introduction
Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for
50% of HF cases.1 HFpEF is associated with morbidity and mortality
close to that of HF with reduced ejection fraction (HFrEF) and there are
no effective therapies.2,3 Both HFrEF and HFpEF are associated with im-
paired endothelial function and a number of studies in patients with
HFrEF have demonstrated that tissue responsiveness to direct nitric ox-
ide (NO) donors in blood vessels and platelets are diminished.4,5
Atrial fibrillation (AF) commonly accompanies HFpEF (up to 40%) and
its presence is associated with substantial embolic risk. Although warfarin
or non-vitamin K antagonist oral anticoagulants are commonly pre-
scribed in this setting the haemorrhagic risk in these patients (mainly el-
derly, often with comorbidities) is high. Trials have shown that aspirin is
relatively ineffective in reducing embolic risk in patients with chronic AF6
and additional therapies that might reduce embolic risk, particularly in
those at high risk of bleeding complications from warfarin would be po-
tentially valuable.
Recent onset AF is itself associated with platelet hyperaggregability, in
part related to impaired NO signalling.7 It is well-established that NO is
an important mediator in the regulation of vascular tone and inhibitor of
platelet aggregation.8 These effects are predominantly mediated by the
activation of soluble guanylate cyclase (sGC) and cyclic guanosine-3’,
5-monophosphate (cGMP), which subsequently activates protein kinase
G and leads to phosphorylation of vasodilator-stimulated phosphopro-
tein (VASP).9
Circulating blood platelets exhibit abnormalities in patients with acute
coronary syndrome (ACS), stable angina and ischaemic HFrEF, and po-
tent antiplatelet therapy plays a pivotal role in management of patients
with ACS.10 The phenomenon of ‘platelet NO resistance’ has been well
described in these patient cohorts,11 but the mechanism of this dimin-
ished anti-aggregatory effect of NO in platelets remains poorly defined.
However, it has been postulated that NO resistance is likely to be associ-
ated with NO scavenging by superoxide believed to be derived predomi-
nantly from circulating neutrophils.12 Other proposed mechanisms
include, oxidation or loss of the haem moiety and/or oxidation of specific
cysteine thiols of the sGC, thus resulting in an impairment of NO-
induced sGC activity.13,14 NO resistance has also been described as an
independent predictor of increased mortality and morbidity in patients
with high risk ACS.15 An alternative route to activate the NO-sGC-
cGMP pathway would therefore be beneficial.
We have previously demonstrated that short-term intravenous so-
dium nitrite improves cardiac and pulmonary haemodynamics in patients
with HFrEF,16 and very recent studies have shown that nebulized nitrite
improves rest and exercise haemodynamics in HFpEF and that sodium
nitrite infusion improves exercise capacity in HFpEF.17,18 Although nitrite
can be reduced to NO under hypoxic/acidic conditions some vasodila-
tion is observed even under normoxic conditions, potentially via a NO-
independent mechanism.19
We have therefore undertaken a study to evaluate the potential of ni-
trite to circumvent ‘platelet NO resistance’ and to compare responses
to nitrite vs. the NO donor SNP in platelets from patients with HFpEF
with chronic AF (HFpEF-AF) with those from healthy volunteers (HVs)
and patients with chronic AF alone. Our results demonstrate that plate-
let NO resistance exists in HFpEF-AF patients, but is not observed in
age-matched patients with chronic AF without HF. Since this phenome-
non was observed in washed platelets; it must be largely independent of
superoxide production by neutrophils and intrinsic to the platelet. We
also show that platelet aggregation in HFpEF-AF is inhibited by nitrite,
and that this effect was not impaired when compared with that seen in
HV and chronic AF.
2. Methods
2.1 Subjects
We studied 12 HVs (8 males and 4 women), 29 patients diagnosed with
HFpEF-AF (21 males and 8 women), 8 age-matched patients with
chronic AF without HF or known coronary artery disease (4 males and 4
women). The HVs and patients were randomly assigned to the pharma-
cological experiments, with 8–11 participants per treatment group.
Sixteen young HVs (9 males and 7 females) were also recruited for west-
ern blotting experiments. HVs were non-smokers free of any cardiovas-
cular risk factors, not on any regular medications, and in particular had
not taken anti-platelet drugs in the 10 days prior to the study. All patients
met the established criteria for the diagnosis of HFpEF-AF.20,21 This in-
cluded participants who have permanent AF and ejection fraction >55%
(established by echocardiography during screening).22,23 Chronic AF
participants included persistent AF with no evidence of HF or known
coronary artery disease. All participants gave written consent before
participation in the study. The investigation conforms to the principles
outlined in the Declaration of Helsinki. The studies were approved by
the University of Birmingham Ethics Review Committee (ERN_10-0625
and ERN_12-1184R2) and West Midlands Coventry and Warwickshire
research ethics committee (14/WM/1211 and 12/WM/0344).
2.2 Blood sampling and platelet
preparation
Venous blood was drawn in 9NC coagulation sodium citrate 3.2% vacu-
tainer tube (Greiner Bio-One, Austria). A preparation of washed plate-
lets was obtained as previously described in.24,25 Whole blood was
centrifuged at 200 g for 20 min and platelet rich plasma (PRP) was col-
lected up to 0.5 cm from the interface with the red blood cell (RBC) pel-
let in order to minimize RBCs contamination. Platelets were isolated
from PRP by centrifugation at 1000 g for 10 min following addition of
PGI2 (0.1 mg/ml; to inhibit platelet activation; Sigma Aldrich). The result-
ing platelet pellet was resuspended in Tyrode’s buffer (134 mM NaCl,
0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5
mM glucose, 1 mM MgCl2, pH 7.3) and centrifuged at 1000 g in the pres-
ence of 0.1 mg/ml PGI2. The supernatant was discarded and the platelet
pellet was resuspended in Tyrode’s buffer. The washed platelet suspen-
sions were allowed to rest for 1 h prior to experimentation to allow the
effects of PGI2 to decay. The level of contamination of our washed plate-
let preparation with plasma constituents was determined using the Bio-
Rad assay for protein determination.
2.3 Assessment of RBC and leukocyte
contamination in washed platelet
preparations
Flow cytometry was used to determine RBC and leukocyte contamina-
tion in washed platelet preparations. Platelets (2  108/ml in Tyrode’s
containing 10% heat deactivated human serum) and RBC (diluted 1:500
in Tyrode’s buffer) were stained with the RBC surface marker PE-
conjugated anti CD235a (eBioscience) or isotype IgG control
(eBioscience) for 20 min in the dark. Cells were washed and acquired
with a C6 Accuri flow cytometer. RBC was gated using anti-CD235a
(eBioscience) and applied to the washed platelet preparation to assess
1314 A. Borgognone et al.
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..RBC contamination. To assess leukocyte contamination in preparations
of washed platelets, platelets and leukocytes were labelled with anti-
CD45 antibody-allophycocyanin (APC; Beckman Coulter) or isotype-
APC control (Beckman Coulter) for 30 min at 4C. In total 0.3 ml of
blood was fixed using 2% formaldehyde for 10 min and after centrifuga-
tion at 500 g for 5 min, blood was resuspended in 3 ml ACK
(Ammonium-Chloride-Potassium) lysis buffer for 10 min to remove
RBCs. Cells were labelled and washed in PBS at 500 g for 5 min and
resuspended in 300 ll PBS for analysis on a C6 Accuri flow cytometer.
Leukocyte populations isolated from whole blood were separated based
on forward scatter and CD45 expression. Gates based on this distribu-
tion were used to assess leukocytes present in preparations of washed
platelets.
2.4 Oxyhaemoglobin preparation
Human haemoglobin (Sigma Aldrich) was dissolved in water (20 mg/ml)
and reduced by a 10-fold molar excess of sodium dithionite (Na2S2O4;
Sigma Aldrich). Excess reductant was removed by gel filtration over
Sephadex G-25 (PD10 desalting column; GE Healthcare) according to
the manufacturer’s instructions. Oxyhaemoglobin (OxyHb) was eluted
with 3.5 ml of water, and only the middle run was collected. The concen-
tration of OxyHb was determined spectrophotometrically, as described
in.26 Aliquots of the OxyHb stock solution were kept at -80C, thawed
on the day of experimentation and discarded after use.
2.5 Platelet aggregation
Washed platelets were suspended at 2  108/ml for light transmission
aggregation using a lumi-dual aggregometer (model 460VS; Chronolog,
Labmedics) under continuous stirring at 1200 rpm, as previously de-
scribed in.24 Sodium nitrite, sodium nitrate, sodium nitroprusside (SNP),
1H-[1, 2, 4]Oxadiazolo[4, 3-a]quinoxalin-1-one (ODQ), 2-Phenyl-4, 4,
5, 5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) (all purchased from
Sigma Aldrich), OxyHb, BAY 41-2272, or vehicles were incubated for
the stated time and concentrations as indicated in the figure legends be-
fore platelet activation with 3 mg/ml collagen (Nycomed).
2.6 Western blotting
Washed platelets were suspended at 5  108/ml for western blot
experiments. Platelets were incubated as indicated in the figure legends.
Incubations were stopped by adding 5 reducing sample buffer at the in-
dicated time point. Samples were boiled for 5 min and spun prior to so-
dium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
(10%) and transferred onto a polyvinylidene fluoride (PVDF; GE
Healthcare) membrane. PVDF membranes were incubated with anti-
bodies against p-Serine 239 VASP (Cell signalling Technology) and a-tu-
bulin (Sigma Aldrich) overnight at 4C. Membranes were then incubated
with appropriate secondary antibodies [anti-rabbit (GE healthcare) and
anti-mouse (Dako)] as detailed in figure legend text. Band densitometry
was performed as previously described in.27
2.7 Statistical analysis
Results are presented either as representative experiment of n experi-
ments performed or as average ± SEM. Differences between groups
were analysed using the, Fisher’s exact test, unpaired t test, one- or two-
way ANOVA by Dunnett’s or Sidak’s multiple comparisons test as ap-
propriate. Within group differences was assessed by Wilcoxon
matched-pairs signed rank test. P < 0.05 was considered significant. All
analyses were performed using Prism version 7.0 (GraphPad Inc., Lo
Jolla, CA).
3. Results
3.1 HVs and HF patients’ characteristics
Table 1 summarizes the subject characteristics including drug
therapies. Patients and healthy controls were well matched in terms of
age (P = 0.40; one-way ANOVA) and gender (P = 0.53; Fisher’s exact
test). Young HVs (whose blood was used for platelet isolation and west-
ern blotting) were well matched in terms of gender to HFpEF-AF group
(P = 0.33; Fisher’s exact test).
3.2 Washed platelet preparation
All experiments presented in this study utilized a preparation of washed
platelets in order to exclude the interference of other blood cell types
and to minimise the contribution of plasma proteins and other blood cell
types to the effects that nitrite may have on platelet function. RBCs in
particular contain (haeme-mediated) nitrite reductase activities, which
are able to reduce nitrite to NO, potentially augmenting the inhibitory
effects of nitrite on platelets. Perhaps even more importantly, RBCs also
contain high concentrations of oxygenated haemoglobin, which is an ef-
fective NO scavenger. Contamination of RBCs was evaluated in our
platelet preparation by FACS as shown in Figure 1A and B, <0.035 ±
0.02% RBC contamination was present in a preparation of washed plate-
lets. Contamination by leukocytes was also excluded using a similar ap-
proach. Figure 1C and D shows that CD45 positive cells were effectively
absent from washed platelet preparations; on average fewer than 1 leu-
kocyte per 1000 platelets were found to be present (Figure 1D), and
......................................................................................................
Table 1 Subject characteristics of HVs, HFpEF with
chronic AF, and chornic AF
Parameter HVs
(n5 12)
HFpEF
with chronic
AF (n5 29)
Chronic
AF (n5 8)
Sex (M/F) 8/4 21/8 4/4
Age, year (mean ± SD) 71.3 ± 5.9 74.3 ± 6.2 73.9 ± 7.9
NYHA-Class I/II/III/ – 23/11/2 –
Diabetes mellitus – 2 2
ACE-inhibitors – 10 2
Angiotensin II receptor blocker – 2 2
Diuretics – 2 4
b-adrenoceptor antagonists – 8 6
a-adrenoceptor antagonist – 2 –
Calcium channel blocker – 9 1
Statins – 10 2
Cardiac glycoside – – –
Digoxin – 4 2
Anti-arrhythmic – – 1
Anti-diabetic – 2 2
Anti-coagulant – 26 8
Values are mean ± SD.
NYHA, New York Heart Association classification; HFpEF, Heart Failure with
preserved ejection fraction; ACE-inhibitors, angiotensin-converting enzyme
inhibitors.
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..plasma proteins concentration was confirmed to be negligible in the sec-
ond washed platelets (-2 ± 0.01%) when compared with PRP (100 ±
0.55%) and first wash (20 ± 0.01%; Figure 1E).
3.3 Nitrite circumvents ‘platelet NO
resistance’ in patients with HFpEF and
chronic AF
Concentration response to collagen (1, 3, and 10 lg/ml) was conducted
to determine the concentration used for platelet aggregation
experiments (data not shown). A collagen dose (3 lg/ml) that achieved a
50% aggregatory response in platelets was selected for this study.24 The
effects of nitrite on platelet aggregation in HV, HFpEF-AF, and chronic
AF patients alone were studied using 3 lg/ml collagen (Figure 2A).
Incubation with nitrite in HVs induced significant concentration-
dependent inhibition of platelet aggregation in response to collagen
(P < 0.0001 at 100 mM and 1 mM; n = 10; Figure 2A), indicating that nitrite
is able to affect platelet function in the absence of other cell types or ex-
tracellular proteins. A similar trend was also observed with the NO do-
nor, SNP, with significant concentration-dependent attenuation of
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Figure 1 Staining of RBCs and leukocytes in a preparation of washed platelets. RBCs and platelets were stained with 0.2 mg anti-CD235a PE-conjugated
antibody or with IgG isotype control. Representative overlay plots are shown (RBCs on the left and platelets on the right) (A). A gate was drawn to include
97–99% of RBCs and applied to the washed platelet sample; cells in the gate were counted as RBCs contaminating the preparation (B, n = 8). RBCs were
lysed in whole blood and the remaining cells or a suspension of washed platelets were stained with APC-conjugated anti-CD45 or with IgG isotype control.
Representative overlay plots are shown (blood on the left and platelets on the right) (C) A gate was drawn around the leukocyte population (D, left panel)
and applied to the washed platelet sample stained with CD45 or isotype control (D, centre and right panel, respectively) (n = 3). (E) Assessment of plasma
protein contamination was determined in washed platelets (first and second wash) and compared with PRP (n = 3).
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platelet aggregation at 10 and 100 nM in response to collagen (P < 0.01
at 10 nM and P < 0.0001 at 100 nM; n = 8; Figure 2B).
We next investigated whether nitrite inhibited platelet aggregation
following administration of 3 lg/ml collagen (Figure 2A) in patients from
HFpEF-AF. Nitrite significantly attenuated platelet aggregation with 1
mM nitrite (P < 0.0001; n = 10), whilst SNP (10 and 100 nM) showed no
diminution of response to collagen activated platelets (n = 8; Figure 2B).
To determine whether increased concentrations (1 and 10 mM) of SNP
attenuated platelet aggregation in HFpEF-AF group, we observed that
SNP caused 45.20 ± 5.45 and 43.11 ± 5.0% inhibition in aggregation, re-
spectively (see Supplementary material online, Figure S1).
To validate whether the SNP responses to collagen were more mark-
edly affected than those of nitrite in the HFpEF-AF group, we compared
the differences in nitrite and SNP response to collagen at the highest
doses used to their respective control HFpEF-AF. As shown in Figure 2C,
10 mM SNP (13.15 ± 3.5% inhibition) demonstrated impaired responses
compared with 1 mM nitrite (29.12 ± 5.4% inhibition; P < 0.05).
To ascertain whether the platelet responses observed with nitrite and
SNP in HFpEF-AF patients were attributable to the HF, the chronic AF
or both we then measured platelet aggregation responses in a sub-group
of patients with chronic AF alone. Both nitrite and SNP induced
concentration-dependent attenuation of platelet aggregation in response
to collagen (Figure 2A; P < 0.0001 nitrite (1 mM); and Figure 2B; P < 0.01
(10 nM) and P < 0.0001 (100nM) SNP, respectively). Representative
traces for HV, HFpEF-AF and cAF alone are shown in Figure 3.
To assess the mechanism by which high concentrations of nitrite cir-
cumvent platelet NO resistance, we first assessed whether nitrite is con-
verted to NO under these experimental conditions by using
two different NO scavengers (PTIO and OxyHb). In both HVs [Figure 4A
(n = 8) and Figure 4B (n = 11)] and patients with HFpEF [Figure 4D (n = 8)
and Figure 4E (n = 9)], neither PTIO nor OxyHb were able to revert the
inhibition caused by a high concentration of nitrite on platelet aggregation.
In order to test the efficacy of PTIO and OxyHb we also assessed aggre-
gation in HVs in the presence of the NO donor SNP. As depicted in
Figure 4A and B, inhibition to SNP was reversed by both NO scavengers.
To delineate the possible role for sGC, we used the sGC inhibitor,
ODQ in combination with an inhibitory concentration of nitrite and
studied collagen aggregation (Figure 4C and F). ODQ reverted SNP-
dependent inhibition in HV and nitrite-dependent inhibition in both
healthy subjects (Figure 4C; n = 8) and HFpEF-AF (Figure 4F; n = 9), indi-
cating that nitrite indeed acts through sGC. Representative traces for
Figure 4 are shown in Supplementary material online, Figure S2.
Interestingly, the sGC dependent effect of nitrite on HV platelets exhib-
ited synergistic activity with the NO-independent sGC activator, Bay
41-2272 (P < 0.001 30 nM Bay 41-2272 plus 10 and 100 mM nitrite, re-
spectively; n = 11, see Supplementary material online, Figure S3B). A simi-
lar trend was also observed with SNP as a positive control (30 nM Bay
41-2272 plus 10 nM SNP (P < 0.01) and 100 nM SNP (P < 0.001), respec-
tively; see Supplementary material online, Figure S3C).
3.4 Nitrite phosphorylates serine-239
VASP
To confirm that the effects of nitrite on platelet aggregation occur via
the activation of the sGC-cGMP pathway, we next studied the status of
phosphorylation of the cyclic nucleotide downstream substrate VASP. In
order to understand the normal physiology vs disease physiology of ni-
trite mechanism in washed platelets, VASP serine-239 phosphorylation
(mainly dependent on cGMP elevation) was assessed from young HVs
vs. HFpEF-AF (Figure 5A and B). VASP serine-239 phosphorylation was
increased with nitrite in a concentration-dependent manner as com-
pared with the NO donor SNP. All concentrations of nitrite reached a
peak after 5–10 min of incubation and then decreased to low levels at 45
min. VASP serine-239 phosphorylation with 100 mM and 1 mM nitrite
were similar to that triggered by treatment with 10 and 100 nM SNP, re-
spectively (n = 5).
To determine whether the underlying mechanism of nitrite was NO
dependent or independent, we measured serine-239 phosphorylation of
VASP following the use of PTIO and OxyHb. We found that in the pres-
ence of NO scavengers, VASP serine-239 was phosphorylated by nitrite
in both young HVs (Figure 6A and B; n = 9) and HFpEF-AF patients (Figure
6C and D; n = 10). We next investigated whether nitrite activated sGC
Figure 2 Platelet aggregation is inhibited by NaNO2. 2  108/ml
washed platelets from HVs, HFpEF-AF and chronic AF alone were incu-
bated with increasing concentrations of NaNO2 or SNP for 5 min, acti-
vated with 3 mg/ml collagen (A and B) and studied by light transmission
aggregometry. Statistical differences were determined by repeated
measures two-way ANOVA with Dunnett’s test for multiple compari-
sons with the control dose values (**P < 0.01, ****P < 0.0001; n =
8–10). (C) Platelet responses to nitrite and SNP in the HFpEF-AF group.
The difference between nitrite (1 mM) and SNP (10 mM) responses to
collagen with their respective control HFpEF were analysed. *P < 0.05
unpaired t test with Welch’s correction (n = 8–10).
Nitrite improves platelet function in HFpEF-AF 1317
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..to phosphorylate serine-239 VASP. VASP phosphorylation on Serine-
239 triggered by nitrite was completely blocked by ODQ in both HVs
and patients with HFpEF-AF, thus corroborating our findings from plate-
let aggregation experiments (Figure 4A–F).
3.5 Nitrate does not affect platelet
aggregation and VASP phosphorylation
The effects of oral inorganic nitrate are usually considered to be depen-
dent on enterosalivary circulation of nitrate with reduction of salivary ni-
trate to nitrite by oral bacteria, but a direct effect of nitrate cannot be
excluded. We therefore assessed the effect of a high concentration of
sodium nitrate (1 mM) added in vitro on collagen-induced aggregation in
young HVs (Figure 7A). In the absence of a functional nitrate reductase,
the addition of nitrate to platelets in vitro had no effect on aggregation
(P > 0.05; n = 5) or phosphorylation of VASP serine-239 (Figure 7B).
4. Discussion
In this study, we show several important new findings: first, platelet NO
resistance exist in patients with HFpEF with associated chronic AF com-
pared with age-matched HVs. Second, while NO resistance has been ob-
served in recent onset AF7 we did not observe it in age-matched
patients with chronic AF in the absence of HF. Taken together, these
data suggest that the platelet NO resistance is attributable predomi-
nantly to the HFpEF rather than the associated chronic AF. Third, this
NO resistance was observed in washed platelets indicating that platelet
NO resistance is largely intrinsic to the platelet. Fourth, nitrite inhibits
platelet aggregation in HFpEF-AF patients by circumventing the platelet
NO resistance phenomenon by directly activating sGC and phosphory-
lating VASP serine 239 independent of NO and the interaction with
other formed elements of blood and their constiuents such as mitochon-
dria (neutrophils) or haemoglobin (RBCs).
Figure 3 Representative platelet aggregation traces for experiments performed from Figure 2 are shown. Platelet responses to nitrite and SNP from HVs
(A and B, HV), HF with preserved ejection fraction with chronic AF (C and D, HFpEF-AF) and chronic AF (E and F, chronic AF).
1318 A. Borgognone et al.
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Approximately half of all cases of HF have HFpEF and the syndrome is
frequently associated with AF.28 The pathophysiology of HFpEF is associ-
ated with abnormalities in left ventricular diastolic reserve, impaired sys-
tolic reserve, peripheral and pulmonary vasodilatation, endothelial
dysfunction, and right ventricular dysfunction related to the presence of
pulmonary hypertension (PH).29
Recent studies have postulated that impairment of the NO-cGMP
pathway may also play a contributing factor in the haemodynamic abnor-
malities observed in HFpEF.30,31 However, to our knowledge the role of
the NO-cGMP pathway on platelet function in patients with HFpEF with
chronic AF has not been previously evaluated. It is well-documented
that impaired platelet responsiveness to NO donors (organic nitrates
and SNP) occurs in a number of cardiovascular disease states, such as
ischaemic heart disease, HFrEF, and in new onset of AF.4,7,15 Herein, we
sought to determine whether NO donors also have a similar impact on
the function of platelets isolated from HFpEF patients with chronic AF.
We demonstrate for the first time that ‘platelet NO resistance’ exists in
HFpEF associated with chronic AF. We used SNP, a well-established
NO donor, to evaluate the impact of activation of the sGC-cGMP path-
way on platelet aggregation.4,32 Platelet responsiveness to the NO do-
nor SNP from HFpEF-AF were diminished following platelet activation
with collagen when compared with platelets from HVs.
It is now appreciated that under certain conditions nitrite can serve as
an alternative source of NO in the vasculature and other tissues.19,33
Recent studies have shown that the nitrate-nitrite-NO pathway inhibits
platelet activation.34–36 It has also been suggested that platelets possess
the ability to generate transient NO signals from nitrite in the absence of
other blood cell types through an unidentified mechanism.34
Although the role of endothelial-derived NO on platelet function is
well characterized,37 the mechanism(s) by which nitrite inhibit platelet
aggregation remain poorly defined. Platelets are exposed not only to en-
dothelial NO but also to circulatory nitrite, and this could represent a
source of NO and an alternative mechanism of control of platelet activa-
tion. Basal circulating nitrite levels in human plasma range are typically in
Figure 4 NaNO2 effects on aggregation depend on sGC. 2 108/ml washed platelets from HVs (n = 8–11) were incubated with NO scavengers (A) 100
mM PTIO or (B) 10 mM OxyHb immediately before addition of 1 mM NaNO2 or 100 nM SNP, or (C) sGC inhibitor 10 mM ODQ 15 min. 2 108/ml washed
platelets from HFpEF-AF patients (n = 8–9) were incubated with (D) PTIO, or (E) OxyHB or (F) ODQ. Aggregation was triggered by 3 mg/ml collagen.
Representative traces for all the performed experiments are shown in Supplementary material online, Figure S2. Repeated measures one-way ANOVA with
Dunnett’s test for multiple comparisons was performed to compare SNP and nitrite to control. Differences between control scavengers/inhibitors to nitrite
was evaluated by Wilcoxon matched-pairs signed rank test (*P < 0.05, **P < 0.01, ***P < 0.001).
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the submicromolar range38,39 and this can rise to levels >8 mM upon
therapeutic nitrite application.17,18 However, local concentrations in the
microcirculation of mucosal membranes are likely considerably higher.
In the oral cavity, nitrite concentrations reach micromolar concentra-
tions even under normal physiological conditions, and salivary nitrite
concentrations may reach 1–2 mM after dietary nitrate.40,41 If nitrite
were to be used as a therapeutic agent to treat HFpEF-AF, concentra-
tions of this mediator would exceed those physiological levels by far,
with possible effects on platelet function. A similar scenario is likely to
occur at the alveolar-arterial interface of the pulmonary circulation fol-
lowing therapeutic application of nebulized nitrite.
This study was motivated by the paucity of information on the signal-
ling cascade leading to platelet inhibition by nitrite. Although it is gener-
ally assumed that nitrite requires prior reduction to NO to become
bioactive, this process is remarkably inefficient under normoxic condi-
tions, and not all of its actions appear to be accompanied by the genera-
tion of free NO.19,42 To determine whether nitrite inhibits platelet
aggregation independently of haemoglobin, we used a well-established
washed platelet aggregation technique.43 Washed platelets are routinely
used to assess pharmacological agents on platelet function and mecha-
nism in the absence of plasma proteins, enzymes, and blood cells. Our
results demonstrate that platelets from HV are inhibited by nitrite
through the activation of sGC (as assessed via the sGC inhibitor ODQ;
Figure 4). We next sought to determine whether these effects were NO
dependent. Both NO scavengers (PTIO and OxyHb) effectively reverted
the effects of an inhibitory concentration of SNP on platelet aggregation
(Figure 4). In contrast neither PTIO nor OxyHb were able to revert the
inhibition caused by a high concentration of nitrite on platelet aggrega-
tion from HV. VASP phosphorylation on Ser239 triggered by nitrite was
completely blocked by ODQ (Figure 6), but inhibition was only partial
with PTIO and OxyHb (Figure 6). Collectively, these data indicate that
the antiaggregatory effects of nitrite are only partly mediated by NO.
This is consistent with additional findings showing that the effects of ni-
trite are potentiated by the NO-independent sGC activator Bay
Figure 5 NaNO2 triggers phosphorylation of VASP. 5 108/ml washed platelets from healthy young volunteers were incubated with increasing concen-
trations of NaNO2 or SNP and lysed by addition of SDS containing 5 sample buffer at the indicated time point. Aliquots of the lysates were used for
SDS-PAGE (10%). Blots were probed with anti p-VASP Serine 239 (1:1000) or a-tubulin (1:5000) and the appropriate secondary antibodies (anti-rabbit or
anti-mouse 1:10000). Representative blots (A) and densitometrical analysis of all the experiments performed (B, n = 4–5) are shown.
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41-2272 (see Supplementary material online, Figure S3). It is conceivable,
therefore, that part of the effects of nitrite are mediated by a modulation
of (one or more) cysteine thiols of sGC; whether this is via S-nitrosation
or S-thiolation (e.g. sulphydration or formation of a mixed disulphide
with another low-molecular weight thiol such as cysteine or glutathione,
and therefore oxidation of a regulatory thiol in sGC)13,14 or another
mechanism (such as the loss of haeme, which renders sGC unresponsive
to NO) was beyond the remit of the present study and warrants further
investigation.
Previous studies have suggested that nitrite therapy may not be subject
to the development of tolerance.44 Furthermore, we and others have very
recently explored nitrite as a potential treatment of HF. We have shown
that short-term intravenous sodium nitrite improves cardiac and pulmo-
nary in patients with HFrEF,16 and very recent studies by Borlaug et al.18
have demonstrated that acute nitrite infusion or nebulized nitrite improves
rest and exercise haemodynamics and exercise capacity in HFpEF.17 To as-
sess whether nitrite inhibits platelet aggregation in this group of patients,
we next assessed the effects of nitrite on platelet function. In the presence
of ‘NO resistance’, nitrite inhibits platelet aggregation. To assess the po-
tential mechanism by which nitrite mediates these promising effects, plate-
let responses to nitrite was assessed in the presence of sGC inhibitor or
NO scavengers. We show that the platelet responsiveness to nitrite was
significantly attenuated in the presence of ODQ (Figure 4), but both NO
scavengers were unable to revert the inhibition caused by a high concen-
tration of nitrite on platelet aggregation and VASP serine 239 phosphory-
lation (Figure 6). Herein, we show for the first time that nitrite circumvents
the platelet NO resistance in patients with HFpEF-AF. A similar result was
also observed with our western blot data. However, haeme-containing
components (cytochrome C) of the mitochondrial respiratory chain of
platelets may convert nitrite to NO45 inside of the platelet, thus avoiding
the scavenging by OxyHb or PTIO.
A number of studies have associated AF with inflammation, endothelial
dysfunction and in particular in the new onset AF with impaired platelet
NO response.7 Procter et al. (2015) have previously reported that acute
onset AF is associated with platelet NO resistance, whilst responses to
NO donor (SNP) were not impaired in chronic AF patients. To validate
whether the platelet NO resistance observed in the HFpEF-AF with SNP
was HFpEF dependent and not AF, we also assessed the effects of nitrite
and SNP in a sub-group of patients with chronic AF alone. There was ap-
proximately two-fold variability between HFpEF-AF vs chronic AF sub-
groups with SNP, therefore further supporting platelet NO resistance in
patients with HFpEF-AF. In addition, nitrite also inhibited platelet aggrega-
tion in a dose-dependent manner in the chronic-AF sub-group.
ACE inhibitors have previously been shown to reduce platelet NO re-
sistance.46 Although 10 of the 29 patients with HFpEF-AF were taking
ACE inhibitors, NO resistance was observed whether or not the
patients were taking ACE inhibitors. Two of the eight patients with
chronic AF alone were taking ACE inhibitors, but in contrast platelet
NO responsiveness was not observed in either of these two patients or
the six who were not taking ACE inhibitors.
Previous studies have demonstrated that cGMP plays a key role in de-
termining the functional and haemodynamic abnormalities developing in
HFpEF.30 In this study, we show that cAF in the absence of HF respond
to NO donors and there is a clear difference in response of ‘NO
resistance’ in patients with HFpEF-AF. This suggests that phenotyping of
patients according to their ‘NO-stimulatable’ component in platelet re-
activity might allow to stratify them to different pharmacological treat-
ment (e.g. personalised medicine).
Herein, we have compared the effects of nitrite on platelet function in
patients with chronic AF with and without HFpEF to conclude about
HFpEF. This study could have benefited in having an additional sub-group
of HFpEF patients with sinus rhythm to further validate the study.
However, as local practice, the majority of HFpEF in sinus rhythm were
taking aspirin and therefore we were unable to recruit for this study.
Thus, this remains a major limitation to the current investigation and fur-
ther studies are warranted to clarify the role of nitrite on platelet func-
tion in this particular patient cohort.
A major limitation of the current findings is that the concentrations of
nitrite used in this study are clearly pharmacological, therefore the
observations do not imply a physiological role for normal plasma nitrite
Figure 6 NaNO2 upregulates VASP serine-239 phosphorylation
NO-independently. 5 108/ml washed platelets from HVs (A and B; n =
8–9) or HFpEF-AF patients (C and D; n = 10) were incubated with ODQ,
PTIO, or OxyHb before addition of NaNO2 for 10 min and lysed by addi-
tion of 5 sample buffer. Aliquots of the lysates were used for SDS-
PAGE (10%) and western blot as in Figure 5. Representative blots (A and
C) and densitometrical analysis of all the experiments performed (B and
D) are shown. Statistical differences were determined by one-way
ANOVA and Dunnet’s post-test. Differences within groups (control NO
scavengers/sGC inhibitors vs. nitrite) were evaluated by Wilcoxon
matched-pairs signed rank test (*P < 0.05; **P < 0.01; ***P < 0.001).
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concentrations in the modulation of platelet function. Nevertheless, they
may have implications for therapy. Recent studies have suggested a po-
tentially beneficial effect of the nitrate/nitrite pathway on haemodynam-
ics and exercise capacity in HFpEF, this study raises the potential that
such therapy may also reduce the burden of thromboembolic disease
seen HFpEF patients with chronic AF.
Furthermore, we observed a decreased platelet aggregation response
to collagen in the control chronic AF when compared with age-matched
control groups from HVs and HFpEF-AF patients. To our knowledge the
effects of collagen on washed platelet aggregation from chronic AF has
not been investigated before, but we have previously assessed platelet
aggregation (PRP) in patients with AF on no therapy to have 24% inhibi-
tion of aggregation in response to 2 mg/ml collagen.47 We have reported
the complexity of the events of platelet activation in AF and therefore
further studies are warranted to clarify the role of nitrite and NO donors
in the disease states investigated herein.
In conclusion, we show for the first time that HFpEF is associated with
marked impairment of platelet NO responses and that nitrite circum-
vents the ‘platelet NO resistance’ phenomenon in human HFpEF, at least
in part by acting as a sGC activator. Our findings are consistent with the
notion that thiol oxidation at the level of the NO-receptor, sGC may
play a major role in the phenomenon of ‘NO resistance’; this would
seem to warrant further investigation. Our findings may also have rele-
vance to the condition of PH since coagulation has been implicated in
the pathogenesis of this disease. Although the use of anticoagulation as
part of the treatment in PH remains controversial, recent experimental
studies suggest that nitrite may provide some benefit in this setting.48
Thus, our data implicate an alternative strategy to potentiate efficacy of
direct sGC activation, and perhaps may reduce the risk of thrombotic
complications in PH.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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